Talem and Libera Bio partner for discovery of AI-driven antibodies
16 Mar 2023
Immunotherapy
Preview
Source: Pharmaceutical Technology
Libera Bio and Talem Therapeutics will develop new antibodies for use with MPN delivery. Credit: __Penelope_ / Pixabay.
Talem Therapeutics, a subsidiary of Immunoprecise Antibodies, has entered a multi-target artificial intelligence (AI)-driven antibody discovery collaboration with Libera Bio.
The partnership will use nanotechnology, which was proven in vivo, for providing antibodies inside tumour cells and provides a potential solution to address the medical challenge.
It will use the LENSai Full Suite of Integrated Intelligence Technology from Immunoprecise Antibodies’ subsidiary BioStrand with the Multifunctional Polymeric Nanocapsules (MPN Technology) of Libera Bio.
The MPN Technology provides an elegant way for delivering antibodies inside tumour cells.
The nanocapsules are designed specifically around the antibodies’ physicochemical properties, for protecting them from degradation in the bloodstream.
Additionally, MPNs can provide other biologic modalities or combinations of a biologic as well as a small molecule in the same nanocapsule.
They deliver the compounds through a cell membrane and to intracellular targets.
Under the collaboration, Libera Bio and Talem Therapeutics will together develop new antibodies for use with MPN delivery.
These antibodies will be provided to pharma companies for conducting late-stage development and marketing.
They will investigate two intracellular targets with high unmet patient requirements for providing options to the oncologists who treat them.
Immunoprecise Antibodies CEO and president Dr Jennifer Bath said: “As we continue to push the boundaries of cancer therapy, the ability to target intracellular proteins has been the ‘Holy Grail’ in oncology.
“Libera Bio’s ground-breaking approach of enabling biologics to penetrate the cell membrane and reach previously ‘undruggable’ targets is an exciting development that has the potential to transform the way we treat cancer.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.